Pseudopolymorphic forms of a HIV protease inhibitor
View Patent ↗New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.
2. A solvate having the formula:
3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.
4. The composition of claim 3 wherein the inert carrier is a pharmaceutically acceptable carrier.
5. The composition of claim 4 wherein the pharmaceutically acceptable carrier is a solid inert carrier.
6. A composition comprising a solvate having the formula:
and an inert carrier.
7. The composition of claim 6 wherein the inert carrier is a pharmaceutically acceptable earner.
8. The composition of claim 7 wherein the pharmaceutically acceptable carrier is a solid inert carrier.